Erbitux 100mg Injection
Prescription Required
Marketed By
Merck
Pack of
1 Vial(s) Of 100ml
Salt Composition
Cetuximab Injection
Storage
Keep in cold place
₹81305₹106250
23.48% Off
Inclusive of all taxes
1
Erbitux 100mg Injection
Delivering To: —
All Substitutes
Indication
colon and rectum cancer
Description
Erbitux 100mg Injection is an antineoplastic injection prescribed by the doctor to treat certain types of cancer, primarily squamous cell carcinoma of the head and neck (SCCHN) and colorectal cancer expressing EGFR. Erbitux 100mg Injection contains Cetuximab monoclonal antibody that specifically binds to the Endothelial Growth Factor Receptor that is responsible for blood vessel formation to supply nutrients to cancer cells. Blockage of EGFR leads to cancer cell growth inhibition.
Dosage And Administration
Erbitux 100mg Injection is administered intravenously (In Veins) by a doctor or an experienced nurse. It is advice not to self administer the injection on your own. For personalized dosage ask your doctor about the same. As Dosage is entirely based on the body surface area, type of cancer, its stage as well as patient's overall health.
Mechanism Of Action
Erbitux 100mg Injection contains Cetuximab monoclonal antibody that specifically binds to the Endothelial Growth Factor Receptor that inhibits receptor activation by natural ligands like EGF and blocking signaling pathways that facilitate tumour survival, proliferation, and metastasis. This action leads to reduced tumour growth, increased apoptosis, and enhanced sensitivity to therapies. Additionally, it promotes EGFR down-regulation and recruits immune cells for targeted cytotoxicity against tumours.
Faqs
Erbitux 100mg Injection is used to treat certain types of cancer, primarily squamous cell carcinoma of the head and neck (SCCHN) and colorectal cancer expressing EGFR .
Erbitux 100mg Injection contains Cetuximab monoclonal antibody that specifically binds to the Endothelial Growth Factor Receptor that is responsible for blood vessel formation to supply nutrients to cancer cells. Blockage of EGFR leads to cancer cell growth inhibition.
No, it is not advised to self administer the Erbitux 100mg Injection until and unless you are not a doctor or professional or experienced health care personnel.
No, Erbitux 100mg Injection is not recommended for administration during pregnancy. It causes harm to developing baby in the womb.
Yes, there are serious side effects of Erbitux 100mg Injection such as severe infusion reactions (e.g., anaphylaxis, bronchospasm), cardiopulmonary arrest, interstitial lung disease, severe skin reactions, and hypomagnesaemia.
References
• Vincenzi, B., Schiavon, G., Silletta, M., Santini, D., & Tonini, G. (2008). The biological properties of cetuximab. Critical reviews in oncology/hematology, 68(2), 93-106.
• Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H. J., ... & Moore, M. J. (2007). Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine, 357(20), 2040-2048.
• Bou-Assaly, W., & Mukherji, S. (2010). Cetuximab (erbitux). American Journal of Neuroradiology, 31(4), 626-627.
• Ocvirk, J., & Cencelj, S. (2010). Management of cutaneous side‐effects of cetuximab therapy in patients with metastatic colorectal cancer. Journal of the European Academy of Dermatology and Venereology, 24(4), 453-459.
Related Products
MARKETER DETAILS
Merck
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.